*Correspondence: Antonio Di Sabatino, [email protected] This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Human clinical trials documented about 10.4% average weight loss over six months which is impressive for an oral supplement
The trial included a non-alcoholic fatty liver disease (NAFLD) cohort, where the drug helped patients reduce liver fat and improve insulin sensitivity
Based on the available clinical results, the FDA approved semaglutide for the following indications: In 2017, the FDA approved injectable semaglutide (brand name Ozempic) at a 1mg/weekly dose for treating type 2 diabetes (T2D) based on the results of the SUSTAIN program [12]
The Drug Enforcement Administration (DEA) considers the medication to be highly addictive and even classifies it as a Schedule II controlled substance
Modern multimodality therapy for EC includes not only traditional surgery, chemotherapy, and radiotherapy but also the integration of targeted therapies and immunotherapies
